Press Releases

Press Releases

View all news
Voronoi Licenses Out MPS1-Targeting Solid Tumor Therapy
2021.11.17
⚫ Total milestones of KRW 1 trillion (USD 846 million) with Pyramid Biosciences of the U.S.

Voronoi Inc. (CEOs Daekwon Kim and Hyuntae Kim), a company specializing in the development of precision targeted therapies, announced on the 17th that it has licensed out its MPS1-targeting solid tumor therapy (VRN08) to the U.S. biotech Pyramid Biosciences ("Pyramid") for total milestones of USD 846 million.
Based in Boston, U.S., Pyramid has a management team with experience in the development and commercialization of anticancer therapies such as Opdivo (nivolumab, anti-PD1) and relatlimab (under FDA review, anti-LAG3) at global pharmaceutical companies including Pfizer, Boehringer Ingelheim, Roche, and BMS. Pyramid is currently conducting Phase 1 clinical trials for its anticancer and psoriasis pipeline programs, respectively. Pyramid's advisory board includes clinicians from leading U.S. institutions such as Harvard, Stanford, and MGH.
Inhibiting the MPS1 kinase, a cell cycle regulator, induces mitotic defects during the growth of cancer cells and can thereby treat cancer. Based on this mechanism of action (MOA), Pyramid will develop VRN08 as a treatment for breast cancer and other solid tumors and plans to advance it into clinical trials in the future. CEO Daekwon Kim of Voronoi said, "For cell cycle regulation inhibitors, biomarker and patient selection strategies are extremely important. We are pleased to partner with the experienced team at Pyramid, which has a world-class oncology advisory board."
Kollol Pal, PhD, CEO of Pyramid, said, "We are pleased to add VRN08 to our precision oncology pipeline. We look forward to entering clinical trials for VRN08 in the near future."
Meanwhile, the domestic development of Voronoi's MPS1 therapy has been selected as an R&D project of the Korea Drug Development Fund (KDDF, Director Hyunsang Mook) and is receiving its support.

<Press Reference Material>
Three cumulative global license-out deals worth KRW 2.1 trillion 'prove technological strength'
Three license-out deals in the U.S. and one in Korea in just over a year
This is Voronoi's fourth domestic or overseas license-out, and already its third license-out to a U.S. biotech company. Prior to this deal, Voronoi licensed out an EGFR Exon20 INS-targeting non-small cell lung cancer therapy to NASDAQ-listed ORIC Pharmaceuticals in October 2020 for up to USD 621 million, followed in August of this year by the license-out of a DYRK1A therapy for autoimmune and neuroinflammatory diseases to NASDAQ-listed Brickell Biotech for up to USD 323.5 million. Including the USD 846 million license-out of this MPS1-targeting breast cancer and solid tumor therapy, the cumulative total milestone value of Voronoi's global license-out deals amounts to USD 1,790.5 million, or approximately KRW 2.1 trillion.